{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:29:57Z","timestamp":1790630997455,"version":"4.1.0"},"reference-count":35,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To compare the glycemic response and pharmacokinetics (PK) of ultra-rapid lispro (URLi) versus lispro during manual basal rate reductions (BRRs) before exercise with conventional continuous subcutaneous insulin infusion (CSII) in active adults with type 1 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>This study was a double-blind, four-period, crossover, randomized controlled trial. Exercise (60 min walking at 45\u201355% VO2max) was performed 4 h after a standardized meal, with either a 50% (\u221260 min) or 100% (\u221215 min) BRR before exercise using URLi or lispro. The primary end point was the change in glucose during exercise, and insulin lispro PK was the secondary end point.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Twenty-five participants (mean \u00b1 SD age 36.7 \u00b1 10.3 years; mean \u00b1 SD HbA1c 50.4 \u00b1 8.5 mmol\/mol [6.76 \u00b1 0.8%]; 48% female) completed the study. URLi significantly attenuated the reduction in glucose level compared with lispro during both the 50% BRR (\u221226.8 \u00b1 37 vs. \u221239.0 \u00b1 39 mg\/dL; P &amp;lt; 0.05) and the 100% BRR (\u221246.9 \u00b1 32 vs. \u221260.5 \u00b1 39 mg\/dL; P &amp;lt; 0.01). Circulating insulin lispro concentrations rose in the first 15 min of exercise, but maximum concentration was lower with URLi versus lispro within each BRR strategy. Numerically less hypoglycemia was observed during exercise with URLi (6%) compared with lispro (16%). Following a postexercise meal, faster insulin absorption of URLi resulted in an earlier postprandial glucose lowering compared with lispro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Using URLi in conventional CSII pump therapy provides more effective BRRs prior to exercise compared with lispro, with fewer hypoglycemic events in active adults with type 1 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-2294","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:55:31Z","timestamp":1774536931000},"page":"1185-1193","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":2,"title":["Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion"],"prefix":"10.2337","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5434-7905","authenticated-orcid":false,"given":"Jennifer K.","family":"Leohr","sequence":"first","affiliation":[{"name":"Eli Lilly and Company 1 , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Abitbol","sequence":"additional","affiliation":[{"name":"LMC Diabetes and Endocrinology 2 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren V.","family":"Turner","sequence":"additional","affiliation":[{"name":"Muscle Health Research Centre, York University 3 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Smith LaBell","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 1 , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aritra","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 1 , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Coutant","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 1 , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Riddell","sequence":"additional","affiliation":[{"name":"LMC Diabetes and Endocrinology 2 , Toronto, Ontario, Canada"},{"name":"Muscle Health Research Centre, York University 3 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026062214532911800_B1","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2337\/dc16-1728","article-title":"Physical activity\/exercise and diabetes: a position statement of the American Diabetes Association","volume":"39","author":"Colberg","year":"2016","journal-title":"Diabetes Care"},{"key":"2026062214532911800_B2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41574-022-00756-6","article-title":"Exercise in adults with type 1 diabetes mellitus","volume":"19","author":"Riddell","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"2026062214532911800_B3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1089\/dia.2023.0140","article-title":"The Type 1 Diabetes and Exercise Initiative: predicting hypoglycemia risk during exercise for participants with type 1 diabetes using repeated measures random forest","volume":"25","author":"Bergford","year":"2023","journal-title":"Diabetes Technol Ther"},{"key":"2026062214532911800_B4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1089\/dia.2017.0010","article-title":"The effects of basal insulin suspension at the start of exercise on blood glucose levels during continuous versus circuit-based exercise in individuals with type 1 diabetes on continuous subcutaneous insulin infusion","volume":"19","author":"Zaharieva","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"2026062214532911800_B5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.2337\/dc18-2204","article-title":"Improved open-loop glucose control with basal insulin reduction 90 minutes before aerobic exercise in patients with type 1 diabetes on continuous subcutaneous insulin infusion","volume":"42","author":"Zaharieva","year":"2019","journal-title":"Diabetes Care"},{"key":"2026062214532911800_B6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1089\/dia.2022.0279","article-title":"Late afternoon vigorous exercise increases postmeal but not overnight hypoglycemia in adults with type 1 diabetes managed with automated insulin delivery","volume":"24","author":"Morrison","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2026062214532911800_B7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2337\/dc21-1593","article-title":"A randomized crossover trial comparing glucose control during moderate-intensity, high-intensity, and resistance exercise with hybrid closed-loop insulin delivery while profiling potential additional signals in adults with type 1 diabetes","volume":"45","author":"Paldus","year":"2022","journal-title":"Diabetes Care"},{"key":"2026062214532911800_B8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1177\/19322968221088327","article-title":"Strengths and challenges of closed-loop insulin delivery during exercise in people with type 1 diabetes: potential future directions","volume":"17","author":"Paldus","year":"2023","journal-title":"J Diabetes Sci Technol"},{"key":"2026062214532911800_B9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jcjd.2020.06.003","article-title":"Glucose control during physical activity and exercise using closed loop technology in adults and adolescents with type 1 diabetes","volume":"44","author":"Zaharieva","year":"2020","journal-title":"Can J Diabetes"},{"key":"2026062214532911800_B10","doi-asserted-by":"crossref","first-page":"111874","DOI":"10.1016\/j.diabres.2024.111874","article-title":"An evaluation of how exercise position statement guidelines are being used in the real world in type 1 diabetes: findings from the Type 1 Diabetes Exercise Initiative (T1DEXI)","volume":"217","author":"Jacobs","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"2026062214532911800_B11","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1007\/s00125-024-06234-0","article-title":"Assessing the influence of insulin type (ultra-rapid vs rapid insulin) and exercise timing on postprandial exercise-induced hypoglycaemia risk in individuals with type 1 diabetes: a randomised controlled trial","volume":"67","author":"Molveau","year":"2024","journal-title":"Diabetologia"},{"key":"2026062214532911800_B12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/dia.2021.0221","article-title":"Comparable glucose control with fast-acting insulin aspart versus insulin aspart using a second-generation hybrid closed-loop system during exercise","volume":"24","author":"Morrison","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2026062214532911800_B13","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/dom.14773","article-title":"What is the value of faster acting prandial insulin? Focus on ultra rapid lispro","volume":"24","author":"Heise","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026062214532911800_B14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/dia.2020.0224","article-title":"Compatibility and safety of ultra rapid lispro with continuous subcutaneous insulin infusion in patients with type 1 diabetes: PRONTO-Pump study","volume":"23","author":"Bode","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"2026062214532911800_B15","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/dom.13621","article-title":"BioChaperone lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: a randomized euglycemic clamp study","volume":"21","author":"Heise","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026062214532911800_B16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1089\/dia.2024.0048","article-title":"Multicenter evaluation of ultra-rapid lispro insulin with control-IQ technology in adults, adolescents, and children with type 1 diabetes","volume":"26","author":"Levy","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"2026062214532911800_B17","unstructured":"Eli Lilly and Company. A study of LY900014 (Lyumjev) versus insulin lispro (Humalog) in participants with type 1 diabetes. In: ClinicalTrials.gov. Bethesda, MD, National Library of Medicine, 2024. NLM Identifier: NCT05262387. Accessed 23 January 2025. Available from https:\/\/clinicaltrials.gov\/study\/NCT05262387"},{"key":"2026062214532911800_B18","volume-title":"Design and Analysis of Bioavailability and Bioequivalence Studies.","author":"Chow","year":"2009"},{"key":"2026062214532911800_B19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10928-018-9611-z","article-title":"Modeling the acute effects of exercise on insulin kinetics in type 1 diabetes","volume":"45","author":"Frank","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2026062214532911800_B20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/dom.14563","article-title":"Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog\u00ae in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study","volume":"24","author":"Kazda","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026062214532911800_B21","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/dom.15063","article-title":"Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus","volume":"25","author":"Aronson","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026062214532911800_B22","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s13300-023-01476-4","article-title":"Assessing time in range with postprandial glucose-focused titration of ultra rapid lispro (URLi) in people with type 1 diabetes","volume":"14","author":"Bergenstal","year":"2023","journal-title":"Diabetes Ther"},{"key":"2026062214532911800_B23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/19322968241289963","article-title":"Impact of ultra-rapid insulin on boost and ease-off in the Cambridge hybrid closed-loop system for individuals with type 1 diabetes","volume":"20","author":"Royston","year":"2026","journal-title":"J Diabetes Sci Technol"},{"key":"2026062214532911800_B24","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/dom.16211","article-title":"Postprandial time in tight range with faster insulin aspart compared with standard insulin aspart in youth with type 1 diabetes using automated insulin delivery","volume":"27","author":"Dovc","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026062214532911800_B25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/dia.2023.0509","article-title":"Postprandial glucose excursions with ultra-rapid insulin analogs in hybrid closed-loop therapy for adults with type 1 diabetes","volume":"26","author":"Haliloglu","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"2026062214532911800_B26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1089\/dia.2023.0178","article-title":"A comparison of faster insulin aspart with standard insulin aspart using hybrid automated insulin delivery system in active children and adolescents with type 1 diabetes: a randomized double-blind crossover trial","volume":"25","author":"Dovc","year":"2023","journal-title":"Diabetes Technol Ther"},{"key":"2026062214532911800_B27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1089\/dia.2023.0042","article-title":"Hybrid closed-loop with faster insulin aspart compared with standard insulin aspart in very young children with type 1 diabetes: a double-blind, multicenter, randomized, crossover study","volume":"25","author":"Ware","year":"2023","journal-title":"Diabetes Technol Ther"},{"key":"2026062214532911800_B28","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/dom.14094","article-title":"Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: a phase 1 randomized, crossover study","volume":"22","author":"Heise","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026062214532911800_B29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(17)30014-1","article-title":"Exercise management in type 1 diabetes: a consensus statement","volume":"5","author":"Riddell","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026062214532911800_B30","first-page":"1","article-title":"The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD)","author":"Moser","year":"2024","journal-title":"Horm Res Paediatr"},{"key":"2026062214532911800_B31","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.2337\/dc21-1899","article-title":"Gender differences in strategies to prevent physical activity-related hypoglycemia in patients with type 1 diabetes: a BETTER study","volume":"45","author":"Pr\u00e9vost","year":"2022","journal-title":"Diabetes Care"},{"key":"2026062214532911800_B32","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2337\/dc23-2212","article-title":"Exploring factors that influence postexercise glycemia in youth with type 1 diabetes in the real world: the Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) study","volume":"47","author":"Sherr","year":"2024","journal-title":"Diabetes Care"},{"key":"2026062214532911800_B33","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/dc20-1554","article-title":"Carbohydrate requirements for prolonged, fasted exercise with and without basal rate reductions in adults with type 1 diabetes on continuous subcutaneous insulin infusion","volume":"44","author":"McGaugh","year":"2021","journal-title":"Diabetes Care"},{"key":"2026062214532911800_B34","doi-asserted-by":"crossref","first-page":"E1106","DOI":"10.1152\/ajpendo.00014.2015","article-title":"Exercise effects on postprandial glucose metabolism in type 1 diabetes: a triple-tracer approach","volume":"308","author":"Mallad","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026062214532911800_B35","doi-asserted-by":"crossref","first-page":"1021800","DOI":"10.3389\/fendo.2022.1021800","article-title":"Exercise, type 1 diabetes mellitus and blood glucose: the implications of exercise timing","volume":"13","author":"Fitzpatrick","year":"2022","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/7\/1185\/860621\/dc252294.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/7\/1185\/860621\/dc252294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:53:39Z","timestamp":1782154419000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/49\/7\/1185\/164642\/Ultra-Rapid-Lispro-Has-an-Improved-Pharmacokinetic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,3,26]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-2294","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}